In financial year 2021, the investments in research and development by the leading ten Indian pharmaceutical companies amounted to around 7.2 percent of their total sales. This was a decrease from 8.4 percent in financial year 2020.
R&D investments as a share of sales by the leading ten Indian pharma companies from financial year 2012 to 2021
Basic Account
Get to know the platform
You only have access to basic statistics.
This statistic is not included in your account.
Starter Account
The ideal entry-level account for individual users
- Instant access to 1m statistics
- Download in XLS, PDF & PNG format
- Detailed references
$199 USD / Month *
Professional Account
Full access
Business Solutions including all features.
* Prices do not include sales tax.
Other statistics that may interest you Statistics on
About the industry
10
- Premium Statistic Number of Indian ANDA approvals by the U.S. FDA 2017-2019
- Premium Statistic Rate of approval for Indian pharma ANDA by U.S. FDA 2017-2019
- Premium Statistic Net sales of Indian pharma companies in 2017-2019
- Premium Statistic Value of Indian drugs and pharmaceutical exports FY 2017-2019
- Premium Statistic Operating margin in Indian pharma companies in 2017-2019
- Premium Statistic Net profit margin of Indian pharma industry in 2017-2019
- Basic Statistic AbbVie's R&D expenditures as revenue share 2012-2023
- Premium Statistic Average peak sales forecast per new biopharmaceutical asset 2013-2022
- Basic Statistic Medicine spending in emerging pharmaceutical markets 2026
- Basic Statistic Percentage return on R&D among mid cap biopharma companies 2013-2020
About the region
10
- Premium Statistic Value of drugs and pharma imports from China to India 2019, by segment
- Premium Statistic Drugs and pharmaceutical export value India FY 2023, by leading destination
- Premium Statistic Patented drugs revenue in prescribed drug market in India 2008-2015
- Premium Statistic Lupin's net sales FY 2015-2023
- Premium Statistic Fish and fishery product exports value from India FY 2023, by leading destination
- Premium Statistic Sun Pharma's income FY 2010-2023
- Premium Statistic Sun Pharma's profit after tax FY 2014-2023
- Premium Statistic Dr. Reddy's Laboratories' cash flow FY 2018-2023, by type
- Premium Statistic Dr. Reddy's Laboratories' PAT FY 2014-2023
- Premium Statistic Aurobindo Pharma's revenue FY 2013-2023
Selected statistics
9
- Premium Statistic Merck & Co - expenditure on research and development 2006-2023
- Premium Statistic AstraZeneca's expenditure on research and development 2006-2023
- Basic Statistic Merck & Co cash dividends declared 2006-2023
- Basic Statistic Sanofi's total assets 2007-2023
- Basic Statistic Merck & Co total assets 2009-2023
- Premium Statistic Pfizer's revenues in the U.S. and abroad 2009-2023
- Premium Statistic Johnson & Johnson's number of employees 2004-2023
- Premium Statistic Sales of Johnson & Johnson worldwide 2011-2023, by segment
- Premium Statistic Sales of Johnson & Johnson 2006-2023 by region
Other regions
10
- Basic Statistic Cost to bring biopharmaceutical assets in mid cap companies to market 2013-2020
- Basic Statistic Select prescription drug price percent changes in the US 2010-2017
- Premium Statistic Italy: number of R&D employees of biotech pharma companies 2014-2017
- Basic Statistic Pharmaceutical businesses: R&D employment in the United Kingdom (UK) 2019, by type
- Basic Statistic Sales share of generic pharmaceuticals in Sweden 2008-2023
- Basic Statistic Share of total business expenditure on technology R&D in Australia 2014
- Premium Statistic Biopharmaceutical market size forecast Japan 2011-2020
- Premium Statistic Generic market share of community and hospital pharmacies in Finland 2007-2017
- Premium Statistic Parapharmaceuticals sales in Russia 2019-2020, by product
- Basic Statistic Generic market value share of community pharmacies in Slovakia 2000-2021
Related statistics
10
- Premium Statistic Aurobindo Pharma's expenditure on R&D FY 2017-2022, by type
- Premium Statistic Aurobindo Pharma's net debt to EBITDA ratio FY 2013-2023
- Premium Statistic Aurobindo Pharma's net debt to equity ratio FY 2013-2023
- Premium Statistic Aurobindo Pharma's EBITDA FY 2013-2023
- Premium Statistic Aurobindo Pharma's revenue from U.S. formulations FY 2013-2023
- Premium Statistic Aurobindo Pharma's EBITDA margin FY 2013-2023
- Premium Statistic Aurobindo Pharma's revenue from ARV formulations FY 2013-2023
- Premium Statistic Aurobindo Pharma's revenue share 2023, by market
- Premium Statistic Aurobindo Pharma's revenue from growth market formulations FY 2013-2023
- Premium Statistic Net profit of major pharma companies India 2024
Further related statistics
10
- R&D expenditure in U.S. biotechnology 2009-2010 by type
- MorphoSys' research & development expenditure 2006-2023
- AstraZeneca's revenue from top product Pulmicort 2006-2023
- CVS Health's total assets 2005-2023
- Walgreens gross profit and net earnings in the U.S. 2005-2023
- Number of employees at Sinopharm 2011-2022
- Annual revenue of Sinopharm 2010-2022
- Annual revenue of Shanghai Pharmaceuticals 2011-2022
- GSK's operating profit by division 2006-2021
- Celgene's revenue and net income 2006-2018
Further Content: You might find this interesting as well
Statistics
- R&D expenditure in U.S. biotechnology 2009-2010 by type
- MorphoSys' research & development expenditure 2006-2023
- AstraZeneca's revenue from top product Pulmicort 2006-2023
- CVS Health's total assets 2005-2023
- Walgreens gross profit and net earnings in the U.S. 2005-2023
- Number of employees at Sinopharm 2011-2022
- Annual revenue of Sinopharm 2010-2022
- Annual revenue of Shanghai Pharmaceuticals 2011-2022
- GSK's operating profit by division 2006-2021
- Celgene's revenue and net income 2006-2018
India Brand Equity Foundation. (February 1, 2024). R&D investments as a share of sales by the leading ten Indian pharma companies from financial year 2012 to 2021 [Graph]. In Statista. Retrieved June 01, 2024, from https://www.statista.com/statistics/999279/randd-investments-share-by-pharma-companies-india/
India Brand Equity Foundation. "R&D investments as a share of sales by the leading ten Indian pharma companies from financial year 2012 to 2021." Chart. February 1, 2024. Statista. Accessed June 01, 2024. https://www.statista.com/statistics/999279/randd-investments-share-by-pharma-companies-india/
India Brand Equity Foundation. (2024). R&D investments as a share of sales by the leading ten Indian pharma companies from financial year 2012 to 2021. Statista. Statista Inc.. Accessed: June 01, 2024. https://www.statista.com/statistics/999279/randd-investments-share-by-pharma-companies-india/
India Brand Equity Foundation. "R&d Investments as a Share of Sales by The Leading Ten Indian Pharma Companies from Financial Year 2012 to 2021." Statista, Statista Inc., 1 Feb 2024, https://www.statista.com/statistics/999279/randd-investments-share-by-pharma-companies-india/
India Brand Equity Foundation, R&D investments as a share of sales by the leading ten Indian pharma companies from financial year 2012 to 2021 Statista, https://www.statista.com/statistics/999279/randd-investments-share-by-pharma-companies-india/ (last visited June 01, 2024)
R&D investments as a share of sales by the leading ten Indian pharma companies from financial year 2012 to 2021 [Graph], India Brand Equity Foundation, February 1, 2024. [Online]. Available: https://www.statista.com/statistics/999279/randd-investments-share-by-pharma-companies-india/